Symbol not found

:ADMS   00:00AM GMT
0.00 (0.00%)

Adamas Pharmaceuticals Announces Adamas Will Acquire Global Rights To Osmolex Er For $7.5 Mln

Published: 12/02/2020 12:22 GMT
(ADMS) - Adamas Announces Agreement to Settle Patent Litigation With Osmotica.
Adamas Pharmaceuticals Inc - Adamas Will Acquire Global Rights to Osmolex Er for $7.5 Million.
Adamas Pharmaceuticals - As Result of Agreement, Both Parties Will Drop Their Respective Claims Relating to Patent Litigation.
Adamas Pharmaceuticals Inc - Will Receive Existing Inventory and All Rights to Osmolex Er.
Adamas Pharmaceuticals Inc - Entered a Supply Agreement in Which Osmotica Will Be Sole Manufacturer of Osmolex Er.